



NEW ZEALAND CLINICAL RESEARCH CONFERENCE

Hosted by the New Zealand Association of Clinical Research · www.nzacres.org.nz

REGISTRATION BROCHURE

WELCOME

It is our pleasure to invite you to take part in the 5th Clinical Research Conference "Yesterday, Today and Tomorrow" to be held at the SkyCity Convention Centre in Auckland, on 20th and 21st August 2009.

NZACRes was founded in August 2004 as a non-profit organisation. It is a constituent organisation of the Royal Society of New Zealand, our national Academy of Science. The aim of NZACRes is to provide a forum for clinical researchers in science, healthcare and industry in New Zealand – for exchanging experience, sharing expertise and networking.

Registration opens at noon on the first day of the Conference and you are invited to network with the Exhibition and Poster presenters over lunch before participating in interactive workshops on a variety of topics. An evening cocktail function follows the workshop sessions to give you an opportunity to catch up with your colleagues and peers.

The second Conference day will include key speakers who will address topics LIST TOPICS. There will also be the opportunity to discuss the poster themes with the authors at break times. The meeting will conclude with the announcement of the *Best Poster Award* winner followed by a farewell cocktail function with an opportunity to continue networking.

Extended coffee and lunch breaks have been scheduled to ensure enough time for meeting peers and visiting the commercial exhibits.

We look forward to welcoming you to the 2009 Clinical Research conference.

Your NZACRes Conference Organising Team

ORGANISING COMMITTEE

Tracy Schuurman	Green Lane Coordinating Centre
Tim Sato	Auckland District Health Board
Sarah Curtis	Roche
Michael Gibson	Trident
Helen Mason	Icon
Melissa Montealegre	Pharmaceutical Solutions
Joline Ong	Icon

SPONSOR ACKNOWLEDGEMENT

Special thanks to all our sponsors and supporters for making this conference possible and for their support in the Clinical Research community over the years.



Centre for **Clinical Research**
and **effective practice**
Creating the future of healthcare



Auckland | Ph: +64 9 379 8205 | www.pharma-solutions.co.nz

VENUE

Auckland is New Zealand's premiere convention destination with a diverse range of hotels, attractions and touring options. The venue for the conference – the SkyCity Convention Centre located in the heart of the central business district - has been host to many international conferences and their associated exhibitions. Features include easy transfer of plenary to breakout rooms which facilitates the provision of a varied and dynamic programme, and wide foyers for exhibition booths. All catering and social events will be served in the exhibition area.

PROGRAMME

Thursday 20 August 2009

12:00 - 13:00	Registration Auckland Room 2 and Foyer, Auckland Promenade Welcome, Exhibition & Poster Opening - Auckland Room 2 and Foyer					
13:00 - 14:45	Workshop 1 <i>A National Hepatitis B Screening and Long-Term Follow-up Programme: The Hepatitis Foundation of New Zealand's Experience.</i> <i>John Hornell</i>	Workshop 2 <i>Clinical Trial Design: Demystifying the Protocol</i> <i>Katrina Sharples</i>	Workshop 3 <i>Diabetes NZ - "Why Won't They Take it Seriously?"</i> <i>John Denton & Teresa Cleary</i>	Workshop 4 <i>Māori Health and Clinical Trials - Achieving Mana Whakamaarama</i> <i>Bridget Robson & Matire Harwood</i>	Workshop 5 <i>Equipping You for Accelerated and Long Term Professional and Personal Success</i> <i>Yvonne Godfrey</i>	
14:45 - 15:15	Afternoon Tea					
15:15 - 17:00	Workshop 1 <i>A National Hepatitis B Screening and Long-Term Follow-up Programme: The Hepatitis Foundation of New Zealand's Experience.</i> <i>John Hornell</i>	Workshop 2 <i>Clinical Trial Design: Demystifying the Protocol</i> <i>Katrina Sharples</i>	Workshop 3 <i>Diabetes NZ - "Why Won't They Take it Seriously?"</i> <i>John Denton & Teresa Cleary</i>	Workshop 4 <i>Māori Health and Clinical Trials - Achieving Mana Whakamaarama</i> <i>Bridget Robson & Matire Harwood</i>	Workshop 5 <i>Equipping You for Accelerated and Long Term Professional and Personal Success</i> <i>Yvonne Godfrey</i>	
17:00 - 18:30	Welcome Cocktail Function in association with 					

WORKSHOP SPEAKERS

Workshop 1 – A National Hepatitis B Screening and Long-Term Follow-up Programme: The Hepatitis Foundation of New Zealand’s Experience.

John Hornell - Chief Executive Officer, Hepatitis Foundation of New Zealand



In 1999, New Zealand introduced a targeted programme of Hepatitis B Screening and Surveillance, directed at Maori, Pacific Island and Asian populations in high prevalence areas. The programme screened in excess of 177,000 at-risk individuals, provided vaccination to those non-immune and identified in excess of 12,000 people with chronic hepatitis B infection. The latter group have been enrolled in a regular HBV surveillance program, offering lifestyle advice on minimising associated risks and early referral to treatment services, where required.

Biography: John Hornell trained as a registered nurse some 25 years ago, with an interest in acute surgery. He joined the Scottish Prison service in the late 1980’s, where he developed an interest in viral hepatitis and infectious diseases. In 1988 he was a finalist in the United Kingdom Nurse of the Year Awards and was recognised for his work with inmates in the prison service. In 1997 he emigrated to New Zealand and in 1999 took up the position of Nurse Manager at the Hepatitis Foundation. During the following two years he took on other projects within the organisation and became its Chief Executive Officer in 2002. Over the past 7 years he has transformed the Foundation into a successful organisation, garnering accolades and respect throughout New Zealand and abroad.

Workshop 2 - Clinical Trial Design: Demystifying the Protocol

Katrina Sharples – Senior Biostatistician, University of Otago



When designing a clinical trial the key objective is to ensure the trial will provide reliable answers to study questions while minimising risk to patients. Study protocols specify a number of design features such as randomisation or minimisation, blinding, placebos, intention-to-treat analysis, planned follow-up, interim analyses, techniques for handling missing data, and sample size justifications, which aim to ensure that the impact of bias and variability are minimised. During this workshop we will explore these design features: what they mean from a practical perspective, and why they are important.

Biography: Dr Katrina Sharples is a senior biostatistician for Cancer Trials New Zealand, and is based at the University of Otago in the Department of Preventive and Social Medicine. She gained her initial experience in clinical trials at the Fred Hutchinson Cancer Research Centre in Seattle, while undertaking a PhD in Biostatistics at the University of Washington. Since returning to New Zealand she has worked as a statistician for trials in variety of areas, predominantly cancer and cardiovascular disease, and has gained wide expertise through serving on Data Monitoring Committees. She is currently the Chair of the Health Research Council of New Zealand Data Monitoring Core Committee.

Workshop 3 - "Why Won't They Take it Seriously?"

Understanding the patient's perspective when diagnosed with a chronic condition.



John Denton, General Manager Diabetes NZ Auckland

John has had type 1 diabetes for over 40 years and worked in diabetes related charities for the last 15 years. He is a trained mediator and worked in "change management" for many years.



Teresa Cleary Services Coordinator Diabetes NZ Auckland

As a NZ Registered Dietitian, Teresa has had 25 years insight into the patient's perspective. Over the last 10 years, Teresa has facilitated diabetes self-management education courses and in-service sessions for health professionals working with people with diabetes.

Workshop 4 - Clinical Trials and Māori health – achieving Mana Whakamaarama

Bridget Robson and Matire Harwood



Populations with high health needs can be inadvertently excluded from clinical trials research, potentially leading to increased inequalities in health. Differential representation in trials by age, gender, ethnicity, socioeconomic status, and geographic locality has been observed. This workshop explores the potential role of clinical trials in contributing to equitable health care and health outcomes for Māori. It aims to cover the following:

- What is mana whakamaarama (equal explanatory power)?
- The role of clinical trials in achieving equity in health
- Kaupapa Māori research principles – how might they intersect with clinical trials research?
- Strategies for achieving adequate representation of Māori in research
- Strategies for keeping research effective and safer for Māori

The workshop will be facilitated by Bridget Robson (Te Rōpū Rangahau Hauora a Eru Pōmare, University of Otago Wellington) and Dr Matire Harwood (MRINZ, Tomaiora, University of Auckland, Tamaki Health Care PHO)

Biography: Bridget Robson (Ngāti Raukawa) is the director of Te Rōpū Rangahau Hauora a Eru Pōmare in the University of Otago, Wellington. Her research interests include the social and economic determinants of health (including unemployment), access to and quality of health care for Māori, and the impact of racism and colonialism on Māori health and disparities.

Bridget is currently involved in projects on disparities in health care for cervical cancer, colon cancer, uterine cancer, breast screening, oral health heart disease, heart disease and maternity care. She was a co-editor of *Hauora: Māori Standards of Health IV* (see www.hauora.maori.nz) and an author of *Unequal Impact: Māori and non-Māori Cancer Statistics 1996-2001*. She is interested in the intersection between epidemiology and kaupapa Māori research.

Biography: Matire is a graduate of the Auckland School of Medicine. She currently works in a number of research and clinical roles including Clinical Director at Tāmaki Healthcare, a Māori-led PHO in Auckland and two Senior Research Fellow roles at Medical Research Institute of New Zealand and Tomaiora, the Maori Health Research Unit at the University of Auckland. A major research interest is ethnic disparities in health outcomes particularly for conditions requiring rehabilitation (stroke, TBI, respiratory conditions and CVD). Matire has contributed to the NZ Guidelines for stroke, TBI, AF, Paediatric Asthma and Māori Cardiovascular Action

Workshop 5 - Equipping You for Accelerated and Long term Professional and Personal Success

Yvonne Godfrey



Timeless Leadership

Based on the conference theme of Yesterday, Today and Tomorrow, Yvonne will case study via DVD an extraordinary man who has undergone 750 doses of chemotherapy over 14 years to discuss **Leadership Principles that endure.**

Biography: Yvonne Godfrey is an acclaimed businesswoman, author and speaker, communicating her leadership messages to audiences as large as 12,000 in 23 countries. Her international business record is impressive having led thousands of small business owners for over 3 decades in all conditions – growth, turbulent and ‘flat’ times. She is also an exceptional mentor, helping her clients to gain the professional edge while achieving fulfilment and balance in their personal and work lives.

PROGRAMME

Friday 21 August 2009

08:00 - 09:00	Registration
09:00 - 09:15	Welcome Tracy Schuurman, Helen Mason - NZACRes Conference Organising Committee Stewart Jessamine –Chairperson
09:15 - 10:00	A History of the 'Unfortunate Experiment' at National Women's Hospital Linda Bryder – University of Auckland
10:00 - 10:30	Centre for Clinical Research and Effective Practice Presentation Stuart Ryan
10:30 - 11:00	Cell Xenotransplantation – A Treatment for Here and Now for Many Diseases Bob Elliott – Medical Director, Living Cell Technologies
11:00 - 11:30	Morning Tea – in association with 
11:30 - 12:05	Gastric Bypass – The Importance of Clinical Research Richard Stubbs – Wakefield Gastroenterology Centre
12:05 – 12:30	"Hoops, Hurdles, Obstacles and Advantages – Conducting Clinical Research in the NZ Environment" Chris Jackson – Otago District Health Board
12:30 - 13:30	Lunch - in association with 
13:30 - 14:00	Hepatitis C Ed Gane – New Zealand Liver Transplant Unit, Auckland City Hospital
14:00 - 14:30	Consequences of participating in a study of the natural history of cervical carcinoma <i>in situ</i> Katrina Sharples - Senior Biostatistician, University of Otago
14:30 - 15:00	An Old Drug and Current Techniques: Tomorrow's Personalised Medicine Nuala Helsby, Senior Lecturer, Molecular Medicine & Pathology, University of Auckland
15:00 - 15:30	Afternoon Tea - in association with 
15:30 - 15:50	Drug Safety in Global Trials James Fan – Associate Director, Medical Affairs and Drug Safety/Asia Pacific, ICON PLC
15:50 - 16:20	Yesterday, Today and Tomorrow in Nutrition Research: A Journey from Under to Overnutrition Sally Poppitt – School of Biological Sciences and Medicine, University of Auckland
16:20 - 16:50	Fighting Cancer at the Sharp End: How I Helped Medicine Work for Me Phil Kerslake – Executive, Hutt Valley District Health Board
16:50 - 17:00	Conference Closing and Prize Giving Karin Gruber – President, NZACRes
17:00 – 19:30	Farewell Networking Cocktail Function – Auckland Room 2 and Foyer

Accurate at time of printing

SPEAKERS

Linda Bryder

A History of the 'Unfortunate Experiment' at National Women's Hospital



The 1988 Inquiry into Cervical Cancer at National Women's Hospital concluded that doctors at the hospital had carried out unethical research since the 1960s. This paper addresses that research from the perspective of a medical historian, placing it in the context of international trends of the times, and questions whether unethical practices had occurred.

Biography: Dr Linda Bryder is an Associate Professor of History at the University of Auckland. She completed her doctorate at the University of Oxford in 1985. Her thesis, on the social history of tuberculosis in twentieth-century Britain, was published by Oxford University Press in 1988. She has published widely in the history of medicine, and teaches courses on the subject in the History Department of the University of Auckland. Since 2004 she has been researching the history of the health of women and their babies with a special emphasis on National Women's Hospital. One facet of that research was the 1988 Cartwright Inquiry, which is the subject of Dr Bryder's most recent book, published in August 2009.

Bob Elliott – Medical Director, Living Cell Technologies

Cell Xenotransplantation – A Treatment for Here and Now for Many Diseases



Biography: Professor Elliott trained as a Paediatrician at Adelaide University, South Australia and entered academia in 1962. He undertook research training in Denver and returned as a Senior Lecturer to Adelaide. He moved to New Zealand in 1970 to become the Foundation Professor, Department of Paediatrics at the University of Auckland, and in 1978 Professor of Child Health Research.

During his tenure of that position he discovered a new method of testing newborn children for Cystic Fibrosis that has been adopted internationally, a novel medical method of treating newborn babies with cyanotic heart disease, and some seminal research in the detection of predisposition to diabetes I, and averting its onset.

Prof Elliott is an Emeritus Professor of Child Health Research, is on the Board of the New Zealand Child Health Foundation (NZ) and the Wings Trust (a NZ trust for the treatment of alcohol and drug abuse) and is also patron of the NZ Cystic Fibrosis Foundation. Professor Elliott co-founded Living Cell Technologies Ltd; a company listed on the Australian stock exchange that is aimed at treating disease by live porcine cell transplantation. Professor Elliott has a publication list of more than 200 scientific reports, across a wide range of topics, but mainly diabetes and cystic fibrosis, and latterly xenotransplantation. He is also the inventor of 11 patents.

James Fan - Associate Director, Medical Affairs and Drug Safety/Asia Pacific, ICON PLC

Drug Safety in Global Trials



Drug safety is the process of identifying, evaluating and responding to Adverse Drug Reactions (ADRs) and safety issues concerning medicinal products in clinical trials and during postmarketing surveillance. This presentation will outline a historical background of Drug Safety and will focus on drug safety management in global trials.

It will also explain the procedures on how to perform SUSAR reporting, review specific safety-related topics, the unblinding process for clinical trial safety, describing how CIOMS and Medwatch are used in drug safety, reviewing the process which involves Institutional Review Boards (IRB), regulatory and investigator reporting and case processing for safety data base. This presentation will end with a discussion about the future of safety reporting requirements in Asia.

Biography: Dr James Fan is Associate Medical Director in ICON Clinical Research Ltd, he currently leads a drug safety group in Singapore that monitors and studies the safety of investigational drug in Asia-Pacific for the global clinical trials. He previously held the position of Medical Director in Taiwan-based CRO Protech Pharmservices Corporation, and American Biotech, Optimer Pharmaceuticals, Inc for 7 years. As a certified physician of Internal Medicine, he was trained in the Shanghai Medical University Hospital with over 11 years of clinical practice experience. He was awarded a Master of Business Study from Massey University in New Zealand in 1999.

Ed Gane – New Zealand Liver Transplant Unit, Auckland City Hospital

Hepatitis C



Hepatitis C in the new epidemic in the Western World, with almost 200 million people infected since 1960. Although the infection is usually asymptomatic, most patients develop insidious progressive liver injury. More than 25% will develop cirrhosis and be at high risk of the lethal complications of liver failure and liver cancer. There are an estimated 50,000 New Zealanders with chronic hepatitis C infection. Hepatitis C has now replaced HBV as the leading cause of liver cancer and hepatitis C is now the most frequent indication for liver transplantation, accounting for 40% of adults transplanted at NZLTU. The cost of this epidemic is now more than \$400 million.

Although successful eradication with antiviral therapy will prevent cirrhosis and the complications thereof, current antiviral therapies are unsatisfactory. One years duration of standard-of care pegylated interferon plus ribavirin achieves cure in only 45% of patients who have never been treated before and in less than 10% of those who have failed a previous course of therapy. Given the high prevalence of hepatitis C disease worldwide, the high treatment failure rate and tolerability issues with the current standard of care, there is a substantial unmet medical need to improve and expand therapeutic options for these patient populations.

The development of *in vitro* models of HCV replication and the characterization of the 3D structure of the HCV enzymes, critical for HCV replication during the last 5 years have triggered the development of potent, orally active direct antiviral agents, namely, nucleoside polymerase inhibitors, nonnucleoside polymerase inhibitors, and protease inhibitors. Unfortunately, when used as monotherapy, these drugs generate HCV mutations which confer phenotypic resistance. With protease inhibitors, this leads to loss of effect within 7 days.

Biography: Ed Gane, MBChB, MD, FRACP is an Associate Professor of Medicine at the University of Auckland, New Zealand and Director of the New Zealand Liver Transplant Unit at Auckland City Hospital. Associate Professor Gane has been the Government Clinical Advisor to the National Hepatitis B Screening Programme since its inception in 1998. He was appointed Chairman for the new Ministry of Health Hepatitis C Advisory Board. He is New Zealand's principal investigator for several current phase I, II, III and IV clinical trials of new antiviral therapies for HBV and HCV before and after liver transplantation. He is also a member of the American Association for the Study of Liver Diseases, the Transplant Society of Australia and New Zealand, the International Liver Transplant Society, the New Zealand Gastroenterology Society, and the Gastroenterology Society of Australia. Associate Professor Gane is extensively published, with over 90 first author papers and over 120 oral and poster presentations at a variety of meetings and congresses. He is on the editorial board for *Liver Transplantation*, *Hepatology International* and the *Journal of Gastroenterology and Hepatology*, a regular reviewer of *Transplantation* and *Hepatology*, and an invited reviewer for *The Lancet*.

Nuala Helsby

An Old drug and Current Techniques: Tomorrow's Personalised Medicine



This talk will discuss the potential of pharmacogenetics to improve therapeutic response to cyclophosphamide. Cyclophosphamide, a drug first used in the 1950's, is still in wide use today as both an antineoplastic agent and in certain autoimmune diseases. However, there are considerable differences in therapeutic response between patients. Cyclophosphamide is an inactive prodrug and requires liver metabolism by CYP enzymes to produce the active cytotoxic metabolite. The potential for genetic variability in this liver activation will be discussed. It may be possible to use relatively simple genomic techniques to identify patients at risk of therapeutic failure. Preliminary clinical data using such an approach will also be highlighted.

Biography: Nuala Helsby is a Senior Lecturer in Molecular Medicine and Pathology at the University of Auckland. She has a particular interest in pharmacogenetics and the metabolism of anti-cancer drugs. Genetics, gender, drug-drug interactions and disease may all play a role in the clinical differences in response to and toxicity of drugs. Hence it is important to have an understanding of all these factors to enable development of "personalised medicine". A number of studies are currently in progress to determine the influence of some of these factors on the clinical variation in the metabolic activation of cyclophosphamide. She has collaborative pharmacogenetics research initiatives with scientists in the Faculty of Medical and Health Sciences and clinicians (oncologists, rheumatologists and renal physicians) at Auckland City, Middlemore Christchurch and Wellington hospitals. Nuala is also the co-ordinator of the Auckland Cancer Research Network (www.acrn.auckland.ac.nz) which aims to foster collaborative cancer research between basic scientists and clinicians.

Christopher Jackson

"Hoops, Hurdles, Obstacles and Advantages – Conducting Clinical Research in the NZ Environment"

Biography: After graduating from Otago, Chris commenced post-graduate training in Wellington and Dunedin, specialising in Medical Oncology. During this time I was Senior Resident and worked as a Clinical Lecturer in Medicine. I was awarded the Graham Aitken Nuffield Post-Graduate scholarship to complete my training abroad. I initially held a position as a Clinical Research Fellow in the GI Unit at the Royal Marsden Hospital in London, focusing on phase 2 and 3 clinical trials particularly in colorectal and upper GI cancer. I co-authored a number of academic papers and book chapters on the treatment of upper and lower GI cancers, particularly in the area of multi-modality therapies and targeted treatments in Colorectal Cancer (monoclonal anti-bodies and tyrosine kinase inhibitors). A submission to the American Society of Clinical Oncology Annual Meeting on Colorectal Liver Metastases received a merit award. Whilst at the Marsden I also worked as a Clinical Fellow in Lymphoma, and also worked in the Academic Urology Unit. On completing my fellowship, I was appointed to a Locum Consultant post at the Marsden and was responsible for leading on the development and opening of a satellite treatment unit. With others in our research group, we commenced a trial of a new drug in colorectal cancer to test its effectiveness, with particular interest in its effectiveness in those with a genetic predisposition to colon cancer. Returning to New Zealand for family and lifestyle reasons, I have recently taken up a post as Consultant Medical Oncologist and Senior Lecturer in Medicine with the Southern Blood and Cancer Service and University of Otago. Current research interests include phase 3 clinical trials in colorectal cancer, and translational research in colorectal cancer.

Phil Kerslake

'Fighting Cancer at the Sharp End: How I Have Helped Medicine Work for Me.'



Arguably for most medical clinicians, the course of a cancer patient's disease and their ultimate survival or demise are attributable solely to the nature and stage of the illness and the efficacy of the treatment regimes employed to address it.

In his talk, Phil Kerslake will outline the proactive survival strategies he has employed through six cancer battles across four decades. Phil will discuss why he believes the patient can play a significant role in the outcomes s/he realises through their actions and attitudes.

Biography: Phil is a well-known, six-time cancer survivor whose education in the art and practice of coping with cancer and its treatments for best outcomes began 30 years ago when he was diagnosed with an incurable lymphoma. Phil shared his experiences and perspectives in New Zealand's most popular patient support book, *Life, Happiness... & Cancer: survive with action and attitude*. He presents his messages pro bono to thousands of patients and health care professionals each year and regularly represents the interests of patient support organisations in the media.

Sally Poppitt

Yesterday, Today and Tomorrow in Nutrition Research: A Journey from Under to Overnutrition



Biography: Sally Poppitt is the director of the University of Auckland Human Nutrition Unit, a nutrition trials facility focused on obesity-related intervention trials, and also is Associate Professor in Nutrition in the School of Biological Sciences and the Department of Medicine. She has been living and working in New Zealand for the past 10 years, where from 2006-08 she was also director of clinical trials development at Protomix Corporation working on therapeutics for obesity-related conditions including insulin resistance and diabetes. Prior to that Sally was a research fellow at the MRC Dunn Nutrition Unit based in Cambridge, UK and at the MRC tropical research facility in The Gambia, West Africa.

Stuart Ryan - General Manager, Centre for Clinical Research and effective practice (CCRep)



Biography: Stuart Ryan holds a PhD from the University of Auckland in the field of biological sciences and worked as a research scientist for 4 years publishing in the fields of anaesthesia, Antarctic biology and plant biochemistry and human respiratory physiology. He moved to industry to pursue research management and held the role of Clinical Research Manager for Fisher & Paykel Healthcare. In 2004 Dr Ryan was appointed as General Manager at CCRep and has grown the organisation to a staff of 44 people conducting some 70+ clinical research projects some of which span 3 DHBs. CCRep continues to develop its span of activities most recently leading the development of a NZ standard indemnity agreement for use with industry-sponsored clinical trials.

Katrina Sharples

Consequences of participating in a study of the natural history of cervical carcinoma in situ



This talk will describe the clinical management and outcomes for 1063 women with cervical carcinoma in situ (CIS) diagnosed between 1955 and 1976 at National Women's Hospital in Auckland. The period includes the decade 1965-74, when the natural history of CIS was the subject of an unethical clinical study that entailed withholding treatment with curative intent, together with two periods for comparison (1955-64 and 1975-76). We present a comprehensive analysis of the women's medical encounters (including for cytology smears and biopsy), the frequency and management of positive cytology, and the occurrence of, and deaths from, invasive cancers of the cervix and vaginal vault, according to the period of first diagnosis of CIS and according to initial management.

Richard S Stubbs

Gastric Bypass - The Importance of Clinical Research.



All new procedures should be accompanied by clinical research! Sometimes what we do simply adds incrementally to what we used to do. In these cases it is important to be sure we really are moving forward. Measurement and investigation will confirm this or otherwise. Sometimes new procedures claim to make giant leaps. Again measurement and investigation will show this to be the case – or otherwise. Failure to allow introduction until the case is proven, is to deny benefit to many as it can often be years before the case is proven.

Gastric bypass and bariatric surgery is a case in point. But one with an unexpected twist! Gastric bypass was introduced in 1967 to try to remedy morbid obesity – for which no other reliable solution was known – not then and not now. The academic world largely ignored what was being done – and even scoffed at it! For many years the surgery was principally conducted in small community hospitals. Fortunately many of those who did it recognised the importance of conducting clinical research. Did it work? What were the complications? How could it be improved? Gradually it gained more and more attention. A new Journal sprang up, because the others weren't interested in publishing in the field. Today it is the commonest major operation performed in the USA. One day it will also be the commonest operation performed in New Zealand. But without clinical research it would never have achieved this position. It is possibly the operation to achieve the most remarkable benefits, for such a large number of people – ever to be performed. It reliably achieves major weight loss, it restores or gives self confidence, it removes physical limitations for activity. It changes lives! But that it seems is not all. It cures diabetes, it cures hypertension, it cures dyslipidaemia, it cures polycystic ovary disease and the accompanying infertility. But what is most magic of all is that it is likely to reveal the fundamental basis for these diseases the answer to Insulin Resistance. All this because some recognised the need to conduct clinical research. Few could have realized how important that research would one day turn out to be!

What will be the next gastric bypass?

Biography: Richard is an Otago graduate who completed surgical training in the UK, and a period of fulltime research in the US, before returning to Wellington in 1986. He spent 5 years in the academic Department of Surgery before entering fulltime private practice at Wakefield Hospital where he established what is now the Wakefield Gastroenterology Centre. His practice is confined to the surgery

of the upper GI tract, and he has developed a particular interest and reputation in the management of liver tumours, and the surgery of severe obesity. He is Director of the Wakefield Biomedical Research Unit and runs an active clinical and basic science research programme with a team of some eight scientists. His basic science research programme relates to exploring the fundamental basis of insulin resistance, on which subject he has a particular hypothesis, and the molecular basis of metastasis. He was appointed a Professor with the Wellington School of Medicine and Health Sciences in January 2008 and has since moved his research Group from Wakefield Hospital to the Medical School in Wellington.

EXHIBITION

You will have the opportunity to interact with those involved in clinical research and learn what's new in the marketplace.

SOCIAL PROGRAMME

Networking Drinks

Thursday 20 August 2009

5.00pm – 6.30pm

Delegates: This function is inclusive for full registrations.

Guests: NZ\$40

Networking Drinks

Friday 21 August 2009

5.00pm – 7.30pm

Delegates: This function is inclusive for full registrations.

Guests: NZ\$50

You are warmly invited to meet up with fellow friends and colleagues at the evening functions.

REGISTRATION

REGISTRATION FEES (inclusive GST)	Early Bird	Standard
	Prior to 20 July 2009	After 21 July 2009
NZACRes Member (Full Registration)	NZ\$265	NZ \$325
NZACRes Member (Friday Only)	NZ \$205	NZ \$230
Non Member (Full Registration)	NZ \$365	NZ \$425
Non Member (Friday Only)	NZ \$305	NZ \$330

Full Conference fee includes:

- * Attendance to all conference sessions and workshops
- * Satchel and contents
- * Morning teas, lunches and afternoon teas
- * Networking drinks for 20 and 21 August

Day Registration fee includes:

- * Attendance to Friday's conference sessions
- * Satchel and contents
- * Morning tea, lunch and afternoon tea

To become an NZACRes member, please visit www.nzarces.org.nz

To Register visit

www.nzacres.org.nz

Payment by credit card (secure transmission facilities provided)

Confirmation of your registration and a tax invoice will be sent upon receipt of your Registration Form and payment.

CANCELLATIONS

Should you need to cancel your registration for any reason, you may reassign your registration to another person. Please notify The Conference Company of the replacement delegate's name and contact details.

Tel: + 64 9 360 1240
Fax: + 64 9 360 1242
Email: crc@tcc.co.nz

If you are unable to arrange a replacement, a refund (the full conference fee less an administration charge of NZ\$75) will be made, providing notification is received by 20 July 2009. After this date, refunds will be at the discretion of the Conference Organising Committee.

If, for reasons beyond the control of the Conference Organising Committee, the conference is cancelled, registration fees will be refunded after the deduction of expenses already incurred.

ACCOMMODATION

A block booking has been made at the SkyCity Hotel and special rates have been negotiated which are equal to, if not better than, corporate rates. Room rates **do not** include breakfast.

SkyCity Auckland

These well appointed [rooms](#) include a choice of king or twin sized beds with stylish décor.

- Spacious bedroom (28 square metres)
- King size bed or twin single beds
- Located on lower floors
- Regular 25 inch television
- Light and stylish décor with blonde coloured furniture

Superior Single / Double Room: NZ\$196.88 incl. GST per night

Making a Reservation

Bookings should be made at time of registration by 20 July 2009. After that date no guarantee can be made that rooms will be available. To secure your reservation payment of one night's room rate, a cheque is required, or you may supply your credit card details to guarantee the booking.

Changing your Reservation

Please advise The Conference Company of any change to a reservation rather than contacting the hotel direct.

Telephone: + 64 9 360 1240
Email: crc@tcc.co.nz
Fax Number + 64 9 360 1242

Cancelling your Reservation

If you cancel your accommodation booking prior to 20 July 2009 your accommodation deposit will be refunded in full. After that date, refunds may be subject to cancellation charges levied by the hotel.

Early Access

If you have an early morning arrival and require an early check-in, you will need to reserve your room for the previous night.

For alternative accommodation bookings please contact The Conference Company.

GENERAL INFORMATION

At the Conference

Your Conference pack will be available for collection from the Registration Desk located in the Auckland Promenade. The desk will be open at the following times:

Thursday 20 August	11.00am – 6.00pm
Friday 21 August	8.00am – 6.00pm

Dress Code

Smart casual for all sessions

Parking

SkyCity Car Park (Conference Parking)

Conference guests receive NZ\$18.00 discounted daily parking subject to availability. Vouchers will be available for purchase from the Registration Desk during the conference.

Public rates are available [here](#).

Special Requirements

Please give details of any special diet, special needs or mobility assistance required on your registration form.

CONFERENCE ADMINISTRATORS

If you have any queries about the conference arrangements please contact:

The Conference Company Ltd

Postal Address	Street Address
PO Box 90-040	31c Normanby Road
Auckland	Mt Eden, Auckland
New Zealand	New Zealand

Telephone:	+ 64 9 360 1240
Facsimile:	+ 64 9 360 1242
Email:	crc@tcc.co.nz